TR199701096T1 - Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri. - Google Patents
Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri.Info
- Publication number
- TR199701096T1 TR199701096T1 TR97/01096T TR9701096T TR199701096T1 TR 199701096 T1 TR199701096 T1 TR 199701096T1 TR 97/01096 T TR97/01096 T TR 97/01096T TR 9701096 T TR9701096 T TR 9701096T TR 199701096 T1 TR199701096 T1 TR 199701096T1
- Authority
- TR
- Turkey
- Prior art keywords
- zenleyen
- revleri
- pyrrolil
- lfonamidler
- etkinli
- Prior art date
Links
- 108050009340 Endothelin Proteins 0.000 abstract 3
- 229940124530 sulfonamide Drugs 0.000 abstract 3
- 150000003456 sulfonamides Chemical class 0.000 abstract 3
- 102000002045 Endothelin Human genes 0.000 abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- USZKOIUIZMUMSE-UHFFFAOYSA-N 1h-pyrrole-2-sulfonamide Chemical class NS(=O)(=O)C1=CC=CN1 USZKOIUIZMUMSE-UHFFFAOYSA-N 0.000 abstract 1
- 102000010180 Endothelin receptor Human genes 0.000 abstract 1
- 108050001739 Endothelin receptor Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- WDPJORZQTNVWPF-UHFFFAOYSA-N n-(1,2-oxazol-3-yl)furan-2-sulfonamide Chemical class C=1C=COC=1S(=O)(=O)NC=1C=CON=1 WDPJORZQTNVWPF-UHFFFAOYSA-N 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41619995A | 1995-04-04 | 1995-04-04 | |
| US41707595A | 1995-04-04 | 1995-04-04 | |
| US08/477,223 US5594021A (en) | 1993-05-20 | 1995-06-06 | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR199701096T1 true TR199701096T1 (xx) | 1998-02-21 |
Family
ID=27411089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR97/01096T TR199701096T1 (xx) | 1995-04-04 | 1996-04-04 | Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri. |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP0819125B1 (enExample) |
| JP (3) | JP3233642B2 (enExample) |
| KR (2) | KR100359397B1 (enExample) |
| CN (1) | CN1130355C (enExample) |
| AT (1) | ATE243203T1 (enExample) |
| AU (1) | AU711968B2 (enExample) |
| CA (1) | CA2217169C (enExample) |
| CZ (1) | CZ299246B6 (enExample) |
| DE (2) | DE122006000068I1 (enExample) |
| DK (1) | DK0819125T3 (enExample) |
| EA (2) | EA199900808A1 (enExample) |
| EE (1) | EE9700251A (enExample) |
| ES (1) | ES2201181T3 (enExample) |
| FI (1) | FI973879A0 (enExample) |
| HU (1) | HUP9802034A3 (enExample) |
| NL (1) | NL300251I2 (enExample) |
| NO (1) | NO315607B1 (enExample) |
| NZ (2) | NZ306734A (enExample) |
| OA (1) | OA10621A (enExample) |
| PL (1) | PL186854B1 (enExample) |
| PT (1) | PT819125E (enExample) |
| TR (1) | TR199701096T1 (enExample) |
| TW (1) | TW492966B (enExample) |
| WO (1) | WO1996031492A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| SG87053A1 (en) | 1996-02-20 | 2002-03-19 | Bristol Myers Squibb Co | High melt polymorth of the compound n-(3,4-dimethyl-5-isoxazolyl)-4'- (2-oxazolyl) [1,1'-biphenyl]-2-sulfonamide |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| AU749167B2 (en) * | 1997-04-28 | 2002-06-20 | Encysive Pharmaceuticals Inc. | Sulfonamides for treatment of endothelin-mediated disorders |
| US5783705A (en) * | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| ATE416772T1 (de) * | 1998-07-06 | 2008-12-15 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| ATE309206T1 (de) | 1998-07-08 | 2005-11-15 | Sanofi Aventis Deutschland | Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| CA2380990A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | Substituted aromatic-ring compounds, process for producing the same, and use |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| EP1533311B1 (en) * | 1999-12-31 | 2007-04-25 | Encysive Pharmaceuticals, Inc | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| WO2001049289A1 (en) * | 1999-12-31 | 2001-07-12 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
| AU2464301A (en) * | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| GB0000625D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| ATE478857T1 (de) * | 2000-09-18 | 2010-09-15 | Toa Eiyo Ltd | N-substituierte benzothiophensulfonamid-derivate |
| US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| EP1347051A4 (en) * | 2000-12-26 | 2004-05-26 | Genox Research Inc | METHOD FOR EXAMINING AN ALLERGIC DISEASE |
| CA2479353C (en) * | 2002-03-15 | 2010-09-14 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivative |
| JP4335136B2 (ja) | 2002-08-09 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
| WO2004014851A2 (en) | 2002-08-09 | 2004-02-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
| SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
| SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
| SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
| SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
| SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
| JP5193602B2 (ja) * | 2004-10-14 | 2013-05-08 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールスルホニルメチルまたはアリールスルホンアミド置換芳香族化合物 |
| WO2008124803A1 (en) | 2007-04-10 | 2008-10-16 | Auspex Pharmaceuticals, Inc. | Substituted deuterium enriched thiophenes for the treatment of hypertension |
| EP3150589A1 (en) | 2007-06-08 | 2017-04-05 | MannKind Corporation | Ire-1a inhibitors |
| ES2651293T3 (es) | 2012-01-31 | 2018-01-25 | Eisai R&D Management Co., Ltd. | Derivado de sitaxentán |
| CN107652246B (zh) * | 2017-09-25 | 2020-08-25 | 江苏乾元生物科技有限公司 | 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法 |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| JP7352662B2 (ja) | 2019-06-18 | 2023-09-28 | ファイザー・インク | ベンゾイソオキサゾールスルホンアミド誘導体 |
| EP3831940A1 (en) * | 2019-12-05 | 2021-06-09 | Danmarks Tekniske Universitet | Small molecule inhibitors of crispr-cas associated activity |
| CN112663077B (zh) * | 2021-01-11 | 2022-07-01 | 陕西师范大学 | 一种苯并磺内酰胺类化合物的电化学制备方法 |
| JP7531947B2 (ja) | 2021-06-22 | 2024-08-13 | 株式会社アークメディスン | 化合物、エンドセリンａ受容体拮抗剤及び医薬組成物 |
| AU2022306778A1 (en) | 2021-07-09 | 2024-01-18 | Vicore Pharma Ab | New selective angiotensin ii compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660383A (en) * | 1968-08-14 | 1972-05-02 | Shionogi & Co | Production of iodoisoxazole compounds |
| US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| TW224462B (enExample) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
-
1996
- 1996-04-04 NZ NZ306734A patent/NZ306734A/en unknown
- 1996-04-04 CN CN96193973A patent/CN1130355C/zh not_active Expired - Fee Related
- 1996-04-04 CZ CZ0311697A patent/CZ299246B6/cs not_active IP Right Cessation
- 1996-04-04 WO PCT/US1996/004759 patent/WO1996031492A1/en not_active Ceased
- 1996-04-04 EA EA199900808A patent/EA199900808A1/ru unknown
- 1996-04-04 JP JP53052496A patent/JP3233642B2/ja not_active Expired - Lifetime
- 1996-04-04 PT PT96912600T patent/PT819125E/pt unknown
- 1996-04-04 ES ES96912600T patent/ES2201181T3/es not_active Expired - Lifetime
- 1996-04-04 DE DE1996628740 patent/DE122006000068I1/de active Pending
- 1996-04-04 CA CA002217169A patent/CA2217169C/en not_active Expired - Fee Related
- 1996-04-04 TR TR97/01096T patent/TR199701096T1/xx unknown
- 1996-04-04 AU AU55367/96A patent/AU711968B2/en not_active Ceased
- 1996-04-04 EP EP96912600A patent/EP0819125B1/en not_active Expired - Lifetime
- 1996-04-04 EP EP00113076A patent/EP1048657A1/en not_active Withdrawn
- 1996-04-04 NZ NZ500282A patent/NZ500282A/xx unknown
- 1996-04-04 HU HU9802034A patent/HUP9802034A3/hu unknown
- 1996-04-04 DE DE69628740T patent/DE69628740T2/de not_active Expired - Lifetime
- 1996-04-04 KR KR1019997007068A patent/KR100359397B1/ko not_active Expired - Fee Related
- 1996-04-04 EA EA199700208A patent/EA007107B1/ru not_active IP Right Cessation
- 1996-04-04 KR KR1019970707078A patent/KR100359396B1/ko not_active Expired - Fee Related
- 1996-04-04 DK DK96912600T patent/DK0819125T3/da active
- 1996-04-04 EE EE9700251A patent/EE9700251A/xx unknown
- 1996-04-04 AT AT96912600T patent/ATE243203T1/de active
- 1996-10-04 TW TW085112218A patent/TW492966B/zh not_active IP Right Cessation
-
1997
- 1997-10-01 PL PL96322707A patent/PL186854B1/pl not_active IP Right Cessation
- 1997-10-02 OA OA70095A patent/OA10621A/en unknown
- 1997-10-03 FI FI973879A patent/FI973879A0/fi not_active Application Discontinuation
- 1997-10-03 NO NO19974577A patent/NO315607B1/no not_active IP Right Cessation
-
2001
- 2001-06-06 JP JP2001171692A patent/JP3527217B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-10 JP JP2003318261A patent/JP2004043495A/ja active Pending
-
2006
- 2006-12-13 NL NL300251C patent/NL300251I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR199701096T1 (xx) | Tienil-, Furil-, Pirolil- ve Bifenils�lfonamidler ve Bunlar�n Endotelin Etkinli�ini D�zenleyen T�revleri. | |
| TR199900705T2 (xx) | Endotelin etkinli�ini d�zenleyen s�lfonamidler ve t�revleri. | |
| EE200200363A (et) | Sulfoonamiidid ja nende derivaadid, mis moduleerivad endoteliini aktiivsust | |
| TR200100874T2 (tr) | Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi | |
| ATE284413T1 (de) | Therapeutische peptid derivate | |
| TR200202738T2 (tr) | Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler | |
| BRPI0405210A (pt) | Conjunto de vedação reforçado | |
| DE69922822D1 (de) | Rekombinante haarbehandlungsmittel | |
| ATE245977T1 (de) | Therapeutische substituierte guanidine | |
| BG96323A (bg) | Нов полипептид и анти-нiv лекарство,получено от него | |
| CR20230166A (es) | Anticuerpo anti antígenos de leucocitos humanos (hla) isoforma dq 2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| ATE218857T1 (de) | Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen | |
| ES2180948T3 (es) | Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal. | |
| ATE13433T1 (de) | Peptide als arzneimittel und einige peptide. | |
| TR199801452T2 (xx) | Jinekolojik rahats�zl�klar�n tedavisinde kullan�lan LHRH analoglar� ve anti�strojenlerden m�te�ekkil farmakolojik kombine madde. | |
| ES2127531T3 (es) | Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales. | |
| RU2003138080A (ru) | Фармацевтическая композиция с антигиперлипидемической активностью | |
| ATE48759T1 (de) | Behandlung von anfaellen und hierfuer nuetzliche pharmazeutische zusammensetzungen. | |
| ATE158947T1 (de) | Hautregenerierende kosmetische zusammensetzung | |
| ITRM920506A1 (it) | Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi. | |
| TR200000903T2 (tr) | Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar. | |
| KR930016096A (ko) | 상처 치유 촉진용 조성물 | |
| DE69619530D1 (de) | Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität | |
| AR011586A1 (es) | Agentes antivirales derivados del 6-bencil-1-etoximetil-5-uracilo sustituido y su uso para el tratamiento de infecciones virales | |
| FR2720938B1 (fr) | Composition dermato-cosmétologique et son utilisation. |